PMID- 38238648 OWN - NLM STAT- MEDLINE DCOM- 20240122 LR - 20240202 IS - 1471-2407 (Electronic) IS - 1471-2407 (Linking) VI - 24 IP - 1 DP - 2024 Jan 18 TI - Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study. PG - 107 LID - 10.1186/s12885-024-11860-3 [doi] LID - 107 AB - BACKGROUND: Paclitaxel liposome (Lipusu) is known to be effective in non-small cell lung cancer (NSCLC) as first-line treatment. This study aimed to evaluate the effectiveness and safety of paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor in patients with advanced NSCLC. METHODS: In this multicenter, retrospective, real-world study, patients with advanced NSCLC who were administered paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor in three centers (Peking University People's Hospital as the lead center) in China between 2016 and 2022 were included. Progression-free survival (PFS), overall survival (OS), objective response rate, disease control rate, and adverse events (AEs) were evaluated. RESULTS: A total of 49 patients were included, with 33 (67.3%) receiving paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor as first-line treatment. There were 34 patients (69.4%) diagnosed with squamous cell carcinoma and 15 (30.6%) with adenocarcinoma. The median follow-up was 20.5 (range: 3.1-41.1) months. The median PFS and OS of all patients were 9.7 months (95% confidence interval [CI], 7.0-12.4) and 30.5 months (95% CI, not evaluable-not evaluable), respectively. Patients with squamous cell carcinoma and adenocarcinoma had median PFS of 11 months (95%CI, 6.5-15.5) and 9.3 months (95%CI, 7.0-12.4), respectively. The median PFS was 9.9 months (95%CI, 7.1-12.7) in patients who received the combined regimen as first-line treatment. Treatment-related AEs of any grade were observed in 25 (51.0%) patients, and AEs of grade 3 or worse were observed in nine patients (18.4%). The most common treatment-related AEs were myelosuppression (14.3%) and fever (10.2%). CONCLUSIONS: Paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor prolonged the PFS in advanced NSCLC with acceptable safety, which was worthy of clinical application. CI - (c) 2024. The Author(s). FAU - Li, Ran AU - Li R AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China. FAU - Liang, Hongge AU - Liang H AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China. FAU - Li, Jun AU - Li J AD - Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, China. FAU - Shao, Zhenyu AU - Shao Z AD - Department of Radiation Oncology, Qilu Hospital of Shandong University, 250012, Jinan, China. FAU - Yang, Donghong AU - Yang D AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China. FAU - Bao, Jing AU - Bao J AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China. FAU - Wang, Keqiang AU - Wang K AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China. FAU - Xi, Wen AU - Xi W AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China. FAU - Gao, Zhancheng AU - Gao Z AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China. FAU - Guo, Renhua AU - Guo R AD - Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, China. FAU - Mu, Xinlin AU - Mu X AD - Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China. xinlin169@163.com. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20240118 PL - England TA - BMC Cancer JT - BMC cancer JID - 100967800 RN - P88XT4IS4D (Paclitaxel) RN - 0 (Liposomes) RN - 0 (Immune Checkpoint Inhibitors) RN - 0 (Programmed Cell Death 1 Receptor) SB - IM MH - Humans MH - *Carcinoma, Non-Small-Cell Lung/pathology MH - Paclitaxel MH - *Lung Neoplasms/pathology MH - Liposomes MH - Immune Checkpoint Inhibitors/adverse effects MH - Programmed Cell Death 1 Receptor/therapeutic use MH - Retrospective Studies MH - Immunotherapy/adverse effects MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects MH - *Adenocarcinoma/drug therapy MH - *Carcinoma, Squamous Cell/drug therapy PMC - PMC10797919 OTO - NOTNLM OT - Immune checkpoint inhibitor OT - Immunotherapy OT - Non-small cell lung cancer OT - Paclitaxel liposome COIS- The authors declare no competing interests. EDAT- 2024/01/19 00:42 MHDA- 2024/01/22 06:43 PMCR- 2024/01/18 CRDT- 2024/01/18 23:33 PHST- 2023/06/03 00:00 [received] PHST- 2023/12/20 00:00 [accepted] PHST- 2024/01/22 06:43 [medline] PHST- 2024/01/19 00:42 [pubmed] PHST- 2024/01/18 23:33 [entrez] PHST- 2024/01/18 00:00 [pmc-release] AID - 10.1186/s12885-024-11860-3 [pii] AID - 11860 [pii] AID - 10.1186/s12885-024-11860-3 [doi] PST - epublish SO - BMC Cancer. 2024 Jan 18;24(1):107. doi: 10.1186/s12885-024-11860-3.